Avata Biosciences Holdings

Avata Biosciences is a clinical-stage biopharmaceutical company focused on developing transformative treatments for rare, treatment-resistant childhood epilepsy syndromes. The company's lead program, EPX-100 (clemizole hydrochloride), is a small molecule that modulates serotonin signaling and is currently in a pivotal Phase 3 clinical trial for Dravet syndrome. Avata's approach originated from a high-throughput zebrafish screening platform developed at UCSF, which identifies drugs capable of suppressing spontaneous seizures. In addition to Dravet syndrome, the company is advancing candidates for Lennox-Gastaut syndrome and other rare genetic epilepsies. Formerly known as Epygenix Therapeutics, Avata is headquartered in New Jersey and aims to provide safer, more effective alternatives to current anti-seizure medications.